Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • From the Analyst's Couch
  • Published:

The multiple sclerosis market

Nature Reviews Drug Discovery volume 9, pages 759–760 (2010)Cite this article

Subjects

Over the course of the 1990s, the development of licensed treatments to alter the disease course of relapsing-remitting MS revolutionized the management of this debilitating condition. Interferon-β1b (IFNβ1b) (Betaseron; Bayer Schering) and glatiramer acetate (Copaxone; Teva and Sanofi–Aventis) became the first drugs to delay the progression of the disease. Natalizumab (Tysabri; Biogen Idec and Elan), launched in 2007, has been the only new MS drug to come onto the market in the past 5 years. Now, the market is expected to change dramatically as improved therapies, addressing efficacy and convenience, are in late-stage development.

Current therapeutic options

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Shifting composition for the multiple sclerosis market.

References

  1. Yong, V. W. et al. Interferon β in the treatment of multiple sclerosis: mechanisms of action. Neurology 51, 682–689 (1998).

    Article  CAS  Google Scholar 

  2. Copaxone. Copaxone prescribing information. Copaxone website, [online] (2010).

  3. National Institute for Health and Clinical Excellence. Multiple sclerosis — β interferon and glatiramer acetate. NICE website, [online] (2002).

  4. Boggild, M. et al. Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator. BMJ 339, b4677 (2009).

    Article  Google Scholar 

  5. Novartis. Two-year Phase III study shows Novartis oral MS therapy FTY720 significantly reduces relapses and disability progression. Novartis website, [online] (2009).

  6. The CAMMS223 trial investigators. Alemtuzumab vs. interferon β-1a in early multiple sclerosis. N. Engl. J. Med. 359, 1786–1801 (2008).

  7. Wynn, D. et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon β. Lancet Neurol. 9, 381–390 (2010).

    Article  CAS  Google Scholar 

  8. Datamonitor. Commercial insight: multiple sclerosis — next generation therapies signal the start of a new era. (Datamonitor, 2010).

Download references

Author information

Authors and Affiliations

  1. Trung Huynh, Ph.d., is an analyst at Datamonitor, 119 Farringdon Road, London EC1R 3DA, UK. THuynh@Datamonitor.com,

    Trung Huynh

Authors
  1. Trung Huynh
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Huynh, T. The multiple sclerosis market. Nat Rev Drug Discov 9, 759–760 (2010). https://doi.org/10.1038/nrd3272

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3272

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing